Form 4: VolitionRx Chief Commercial Officer Reports Significant RSU Award and Tax-Related Share Disposition

VolitionRx Ltd.'s Chief Commercial Officer, Gael Forterre, reported the acquisition of restricted stock units as compensation and a corresponding disposition of shares for tax withholding purposes.

Summary

• Gael Forterre, Chief Commercial Officer of VolitionRx Ltd. (VNRX), reported transactions on June 1, 2025, as detailed in a Form 4 filing.
• Mr. Forterre was awarded 6,690 restricted stock units (RSUs) under the Issuer's 2015 Stock Incentive Plan, which were granted in lieu of cash compensation.
• These RSUs are scheduled to vest in three equal installments of 2,230 units on June 1, 2025, July 1, 2025, and August 1, 2025, contingent upon his continued service.
• Upon vesting and settlement, Mr. Forterre will receive shares of common stock equivalent to the number of vested RSUs.
• Additionally, 4,234 shares of common stock were retained by VolitionRx for cancellation to satisfy tax withholding obligations related to the settlement of 10,240 previously awarded restricted stock units.
• It was explicitly stated that no shares were sold by Mr. Forterre or VolitionRx in this tax-related transaction.
• Following these reported transactions, Mr. Forterre directly beneficially owns 161,462 shares of common stock.
• He also holds indirect beneficial ownership of 5,000 shares through his spouse and 32,500 shares through Armorica Partners, LLC, where he serves as the managing director and sole shareholder, though he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a routine Form 4 filing detailing an executive's equity compensation and tax-related share disposition. It does not contain information that would significantly alter the company's financial outlook or operational status, thus indicating a neutral sentiment.

Positives

• The award of 6,690 restricted stock units (RSUs) to Chief Commercial Officer Gael Forterre demonstrates continued executive compensation and aligns management's interests with shareholder value.
• The RSUs were granted in lieu of cash compensation, which could help the company preserve its cash reserves.

Negatives

• A disposition of 4,234 shares of common stock was made by VolitionRx to cover tax withholding obligations for the reporting person, representing a minor reduction in outstanding shares for tax purposes.

Risks

• Potential minor dilution for existing shareholders upon the future vesting and settlement of the 6,690 restricted stock units, as new shares will be issued.

Future Outlook

The awarded 6,690 restricted stock units are scheduled to vest in three equal installments on June 1, 2025, July 1, 2025, and August 1, 2025, contingent on the Chief Commercial Officer's continued service.

Industry Context

This Form 4 filing details a routine equity compensation award and tax-related share disposition for an executive, which is a common practice across various industries to align executive incentives with shareholder value and manage compensation. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• This filing reports standard equity compensation practices (Restricted Stock Units) and tax withholding procedures that are common in publicly traded companies across various sectors.
• The document does not provide specific comparable companies, projects, or results to allow for a direct, detailed comparison to industry benchmarks beyond the general nature of the transaction.

Related Party Transactions

• Award of 6,690 restricted stock units to Gael Forterre, Chief Commercial Officer, in lieu of cash compensation, under the Issuer's 2015 Stock Incentive Plan. This constitutes a transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: Minor potential dilution from the issuance of new shares upon RSU vesting. The tax withholding transaction does not involve a sale of shares into the open market by the executive or the company.
• Employees: The RSU award is part of executive compensation, which can serve to motivate management and align their interests with the company's performance.

Next Steps

• Vesting and settlement of 2,230 restricted stock units on July 1, 2025.
• Vesting and settlement of 2,230 restricted stock units on August 1, 2025.

Key Dates

Keywords

VolitionRx, VNRX, Gael Forterre, Chief Commercial Officer, Restricted Stock Units, RSU, Stock Incentive Plan, Insider Transaction, SEC Form 4, Equity Compensation, Tax Withholding, Beneficial Ownership